Camidanlumab tesirine

camidanlumab tesirine · ADC Therapeutics S.A.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Camidanlumab tesirine, covering 2024-03-28 to 2024-03-28. Get the full timeline:

Most recent: Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma [Phase 2]

See pricing